Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis
- Resource Type
- Authors
- Gladys Martinetti; Enos Bernasconi; Rosaria Sacco; Franco Keller; Giulio Disanto; Chiara Zecca; Claudio Gobbi
- Source
- JAMA Neurol
- Subject
- Adult
Male
COVID-19 Vaccines
Multiple Sclerosis
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Disease
medicine
Research Letter
Humans
In patient
Lymphocyte Count
Anti cd20
skin and connective tissue diseases
Aged
business.industry
Multiple sclerosis
fungi
Antibodies, Monoclonal
COVID-19
Middle Aged
medicine.disease
Antigens, CD20
Fingolimod
Immunity, Humoral
body regions
Immunology
Ocrelizumab
Female
sense organs
Neurology (clinical)
business
Immunosuppressive Agents
Cohort study
medicine.drug
- Language
- English
This cohort study investigates the humoral response to 2 SARS-CoV-2 messenger RNA vaccines in patients with multiple sclerosis treated with fingolimod and ocrelizumab.